Glycan Profiling of Biologic Therapeutics: Analytical Methods and Regulatory Expectations

Glycosylation is not just a quality attribute; it is a critical determinant of efficacy and immunogenicity for every biologic on the market. For monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and biosimilars, the glycan profile attached to a therapeutic protein directly controls how it binds to immune receptors, how long it persists in circulation, and whether it triggers an adverse immune response.

Glycosylation as a critical quality attribute in biologic therapeutics

For IgG-class mAbs, N-linked glycans attach to Asn297 in the CH2 domain of the Fc region, and the specific composition of those glycans determines how the antibody engages Fc gamma receptors on immune effector cells. Alterations in core fucosylation, galactosylation, sialylation, and mannose content each exert distinct effects on receptor binding affinity and downstream cytotoxic activity.

Afucosylation substantially enhances ADCC by increasing affinity for the activating FcγRIIIa receptor, and multiple studies have confirmed that afucosylated antibodies induce higher levels of ADCC compared to their fucosylated counterparts across diverse immune effector cell types. Glycosylation also shapes immunogenicity risk: proteins produced in murine myeloma cells may carry non-human glycan epitopes such as N-glycolylneuraminic acid that are not found in human serum, and as reviewed in BioDrugs, changes to the N-linked glycosylation pattern of the Fc domain can alter both the safety and efficacy of an mAb.

HILIC-FLD: the reference method for N-glycan profiling

Hydrophilic interaction liquid chromatography with fluorescence detection (HILIC-FLD) is the most widely adopted platform for released N-glycan profiling in biopharmaceutical quality control. The workflow begins with enzymatic release of N-glycans using peptide-N-glycosidase F (PNGase F), followed by fluorescent labeling of the reducing end (typically with 2-aminobenzamide, or 2-AB) and HILIC separation with fluorescence detection.

A study demonstrating the robustness of HILIC-FLD and HILIC-MS approaches for quantitative N-glycan profiling of adalimumab and infliximab biosimilar products confirmed good agreement between labeling chemistries and consistent glycoform quantitation across platforms. For regulatory submissions, HILIC-FLD is the method most commonly cited in biologics license applications, with the relative abundance of glycoforms such as G0F, G1F, G2F, and high-mannose species forming a key element of the product specification.

Table 1. Comparison of major glycan profiling platforms used in biologic drug development.

CE-LIF glycan analysis: an orthogonal platform for biopharmaceutical QC

Capillary electrophoresis with laser-induced fluorescence (CE-LIF) is an established orthogonal technique to HILIC-FLD and has gained widespread adoption for high-throughput glycan profiling in bioprocess monitoring and biosimilar comparability dossiers. Released N-glycans are labeled with the charged fluorophore APTS under mild reductive amination conditions that preserve sialic acid and fucose residues, then are separated by charge-to-size ratio through a neutral-coated capillary.

A major interlaboratory CE-LIF study across 20 independent laboratories in the US, Europe, and Asia confirmed that CE-LIF delivers consistent migration time and peak area data when standardized protocols are applied. Because CE-LIF separates primarily by charge while HILIC separates by hydrophilicity, the two platforms provide genuinely complementary information, a distinction that is directly relevant to regulatory strategy, since both FDA and EMA biosimilar guidance expect orthogonal characterization methods to be applied.

LC-MS/MS glycopeptide mapping for structural glycan characterization

LC-MS/MS glycopeptide mapping provides the highest level of structural resolution for glycan characterization and is the method of choice for site-specific glycoform distribution analysis and structural confirmation of less abundant species. The protein is proteolytically digested, typically with trypsin or Lys-C, and the resulting glycopeptides are separated by reversed-phase chromatography and analyzed by high-resolution mass spectrometry.

Glycopeptide mapping satisfies the structural evidence requirement in regulatory filings, complementing the relative quantitation data generated by HILIC-FLD and CE-LIF. The analytical similarity frameworks used for biosimilar dossiers in the US, EU, and other major markets consistently expect mass spectrometric structural evidence alongside chromatographic quantitation, making glycopeptide mapping a mandatory element of the extended characterization package for any biologic seeking marketing approval.

Glycan profiling under ICH Q6B: lot release criteria and regulatory expectations

The ICH Q6B guideline establishes international specifications and test procedures for biotechnological and biological products and is the foundational regulatory framework governing biologic characterization. Under ICH Q6B, glycan profiling is explicitly required as part of molecular characterization, with sponsors expected to identify the carbohydrate structure, glycan profile, and linkage type of glycans attached to the protein.

Lot release acceptance criteria for glycan attributes (including total fucosylation, galactosylation, and high-mannose content) are set based on clinical lot data and the relationship between those attributes and product function. For biosimilars, comparability assessments rely on orthogonal glycan datasets built from both HILIC and CE-LIF platforms, and FDA review of over 150 mAb product submissions has identified nine universal glycan epitopes common across all approved therapeutic mAbs produced by mammalian cell expression systems, supporting more structured comparability strategies.

Glycoengineering and glycan profiling method validation

Intentional glycan modification is now a defined strategy for optimizing biologic efficacy, and the analytical requirements for glycoengineered products are more demanding than those applied to standard complex-type glycoforms. The most clinically advanced approach is afucosylation, where upstream bioprocessing controls (including cell line engineering or small-molecule fucosyltransferase inhibition) are used to shift the glycoform distribution toward G0, G1, and G2 species and away from their fucosylated counterparts.

For a glycoengineered product where afucosylation content defines potency, the glycan profile functions as a potency assay, and ICH Q2(R2) validation requirements for accuracy, precision, specificity, linearity, and range apply in full. Analytical development teams working across the broader biologic characterization platform should plan for a more resource-intensive validation campaign than standard biopharmaceutical workflows require and should coordinate with regulatory affairs on the expected specification strategy early in development.

Glycan profiling as a foundation for biologic approval

Glycan profiling has evolved from a supporting characterization activity into a central pillar of the biologic quality system, directly connecting to the process analytical technology and industrial QC testing strategies applied across modern biomanufacturing. The combination of HILIC-FLD for quantitative release testing, CE-LIF for orthogonal confirmation, and LC-MS/MS glycopeptide mapping for structural elucidation together provides a comprehensive picture of the glycan landscape for any biologic therapeutic.

Building a glycan profiling strategy early, one that integrates validated release methods with extended characterization platforms and supports the biosimilar comparability framework, is the most reliable way to avoid late-stage regulatory delays. The analytical investment required is substantial, but an inadequately characterized glycan profile at the time of a biologics license application filing is a risk no biopharmaceutical development program should take.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.